Show simple item record

dc.contributor.authorCastillo-Olivares, Javier
dc.contributor.authorWells, David A
dc.contributor.authorFerrari, Matteo
dc.contributor.authorChan, Andrew CY
dc.contributor.authorSmith, Peter
dc.contributor.authorNadesalingam, Angalee
dc.contributor.authorPaloniemi, Minna
dc.contributor.authorCarnell, George
dc.contributor.authorOhlendorf, Luis
dc.contributor.authorCantoni, Diego
dc.contributor.authorMayora-Neto, Martin
dc.contributor.authorPalmer, Phil
dc.contributor.authorTonks, Paul
dc.contributor.authorTemperton, Nigel J
dc.contributor.authorPeterhoff, David
dc.contributor.authorNeckermann, Patrick
dc.contributor.authorWagner, Ralf
dc.contributor.authorDoffinger, Rainer
dc.contributor.authorKempster, Sarah
dc.contributor.authorOtter, Ashley D
dc.contributor.authorSemper, Amanda
dc.contributor.authorBrooks, Tim
dc.contributor.authorAlbecka, Anna
dc.contributor.authorJames, Leo C
dc.contributor.authorPage, Mark
dc.contributor.authorSchwaeble, Wilhelm
dc.contributor.authorBaxendale, Helen
dc.contributor.authorHeeney, Jonathan
dc.date.accessioned2021-12-22T15:05:58Z
dc.date.available2021-12-22T15:05:58Z
dc.date.issued2021
dc.date.submitted2021-07-27
dc.identifier.issn1664-3224
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/331693
dc.description.abstractPrecision monitoring of antibody responses during the COVID-19 pandemic is increasingly important during large scale vaccine rollout and rise in prevalence of Severe Acute Respiratory Syndrome-related Coronavirus-2 (SARS-CoV-2) variants of concern (VOC). Equally important is defining Correlates of Protection (CoP) for SARS-CoV-2 infection and COVID-19 disease. Data from epidemiological studies and vaccine trials identified virus neutralising antibodies (Nab) and SARS-CoV-2 antigen-specific (notably RBD and S) binding antibodies as candidate CoP. In this study, we used the World Health Organisation (WHO) international standard to benchmark neutralising antibody responses and a large panel of binding antibody assays to compare convalescent sera obtained from: a) COVID-19 patients; b) SARS-CoV-2 seropositive healthcare workers (HCW) and c) seronegative HCW. The ultimate aim of this study is to identify biomarkers of humoral immunity that could be used to differentiate severe from mild or asymptomatic SARS-CoV-2 infections. Some of these biomarkers could be used to define CoP in further serological studies using samples from vaccination breakthrough and/or re-infection cases. Whenever suitable, the antibody levels of the samples studied were expressed in International Units (IU) for virus neutralisation assays or in Binding Antibody Units (BAU) for ELISA tests. In this work we used commercial and non-commercial antibody binding assays; a lateral flow test for detection of SARS-CoV-2-specific IgG/IgM; a high throughput multiplexed particle flow cytometry assay for SARS-CoV-2 Spike (S), Nucleocapsid (N) and Receptor Binding Domain (RBD) proteins); a multiplex antigen semi-automated immuno-blotting assay measuring IgM, IgA and IgG; a pseudotyped microneutralisation test (pMN) and an electroporation-dependent neutralisation assay (EDNA). Our results indicate that overall, severe COVID-19 patients showed statistically significantly higher levels of SARS-CoV-2-specific neutralising antibodies (average 1029 IU/ml) than those observed in seropositive HCW with mild or asymptomatic infections (379 IU/ml) and that clinical severity scoring, based on WHO guidelines was tightly correlated with neutralisation and RBD/S antibodies. In addition, there was a positive correlation between severity, N-antibody assays and intracellular virus neutralisation.
dc.languageen
dc.publisherFrontiers Media SA
dc.subjectImmunology
dc.subjectCOVID-19
dc.subjectSARS-CoV-2
dc.subjectSerological biomarkers
dc.subjectAntibodies
dc.subjectWHO International Standard
dc.subjectCorrelates of Protection
dc.subjectCOVID-19 immune response
dc.titleAnalysis of Serological Biomarkers of SARS-CoV-2 Infection in Convalescent Samples From Severe, Moderate and Mild COVID-19 Cases.
dc.typeArticle
dc.date.updated2021-12-22T15:05:57Z
prism.publicationNameFront Immunol
prism.volume12
dc.identifier.doi10.17863/CAM.79143
dcterms.dateAccepted2021-10-22
rioxxterms.versionofrecord10.3389/fimmu.2021.748291
rioxxterms.versionVoR
rioxxterms.licenseref.urihttp://creativecommons.org/licenses/by/4.0/
dc.contributor.orcidCarnell, George [0000-0001-8875-0989]
dc.contributor.orcidHeeney, Jonathan [0000-0003-2702-1621]
dc.identifier.eissn1664-3224
cam.issuedOnline2021-11-19


Files in this item

Thumbnail
Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record